Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
This recent comprehensive study sheds light on the rapid expansion of the prostate cancer drugs market, citing key advancements and geographical trends fueling the sector's growth. As reported, the market, estimated at $17.36 billion in 2023, is projected to escalate to $18.55 billion in 2024, marking a significant CAGR of 6.8%. Critical influences driving the escalation include an aging population, increasing diagnoses, advancements in drug development, and heightened awareness.
The continuously evolving healthcare landscape prescribes a bright outlook for the market, with anticipations to reach nearly $23.99 billion by 2028, growing at a CAGR of 6.6%. The forecast period is witnessing innovative trends, such as the rise of precision medicine and the integration of telemedicine in patient care, as well as significant advances in immunotherapy and targeted therapies.
Prostate Cancer Drugs Market Dynamics
- An aging population, particularly among males
- The upsurge in global prostate cancer incidence
- Ongoing research and development yielding novel treatment paradigms
The report delves into various categories of therapies, including hormonal therapy, chemotherapy, and immunotherapy. An emerging trend is the burgeon of combination therapy in tackling prostate cancer, exemplified by drugs like XTANDI (enzalutamide) utilized alongside androgen deprivation therapy.
Navigating through the challenges posed by recurrent or non-responsive prostate cancer remains a focal concern in the growth trajectory. Despite this, developments in the market spotlight the commitment of pharmaceutical companies to innovate and secure regulatory approvals for new products contributing to enhanced treatment outcomes.
Regional Market Highlights
North America dominated the global market in 2023, bolstered by advanced healthcare infrastructure and high rates of patient awareness. Simultaneously, the Middle East is projected to record the fastest growth during the forecast span, attributed to increasing investments in healthcare systems and emerging market penetration.
This comprehensive market analysis provides invaluable insights for stakeholders within the healthcare and pharmaceutical sectors, highlighting the market size, competitive landscape, regional shares, trend analyses, and future market potentials.
Markets Covered:
- By Type: Hormone Sensitive Prostate Cancer; Hormone Refractory Prostate Cancer;
- By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy;
- By End User: Hospitals; Clinics; Other End-Users
A selection of companies mentioned in this report includes
- Astellas Pharma Inc.
- AstraZeneca PLC
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- F. Hoffmann-La Roche AG
- Abbott Laboratories
- Pfizer Inc.
- Novartis International AG
- F. Hoffmann-La Roche Ltd.
- Tolmar Inc.
- AbbVie Inc.
- Siemens Healthineers AG
- Genomic Health Inc.
- OPKO Health Inc.
- Siemens Healthcare GmbH
- MDxHealth SA
- Myriad Genetics Inc.
- Janssen Biotech Inc.
- Clovis Oncology Inc.
- Merck Sharp & Dohme Corp.
- Dendreon Corporation
- Ferring Pharmaceuticals Inc.
- GlaxoSmithKline plc
- Ipsen Biopharmaceuticals Inc.
- Merck & Co. Inc.
- Eli Lilly and Company Inc.
- Bausch Health Companies Inc.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Amgen Inc.
- Biogen Inc.
- Celgene Corporation
- Gilead Sciences Inc.
- Regeneron Pharmaceuticals Inc.
- Agios Pharmaceuticals Inc.
- Exelixis Inc.
For more information about this report visit https://www.researchandmarkets.com/r/7q9l57
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
